HUMA Humacyte, Inc. Insider Trading

Director Sebelius buys 56,818 HUMA shares at $0.88 (+62.3% position increase) while stock trades -68.6% from 52-week high.

Director Kathleen Sebelius purchased 56,818 shares at $0.88 on 2026-05-19, increasing her holdings by 62.3% to 148,025 shares. The purchase occurred when the stock was trading at $0.92, currently 68.6% below its 52-week high of $2.93, though up 33.8% over the prior 30 days. Humacyte remains unprofitable with net income of $-17.6M against quarterly revenue of $495.0K, and the company has a market cap of $204.3M. This buy represents a substantial position increase during a period of depressed valuation relative to recent highs.

Director Brady W Dougan sold entire 2.24M share stake over 3 days for $3.7M; complete exit from unprofitable biotech down 76.9% from 52-week high

Dougan Brady W, a Director at Humacyte, Inc., executed 3 separate sales totaling 2,241,045 shares for $3,733,191.10 across August 18–20, 2025, completely liquidating his holdings at a blended average price of $1.67. This represents a complete exit from the company, liquidating a position at prices substantially depressed: the stock is now $1.63 current price, down 76.9% from its 52-week high of $7.05 and down 29.1% over the prior 30 days. The company's fundamentals remain stressed—latest quarter revenue was only $301,000.00 and the company is unprofitable with net income of $-37,658,000.00 over the most recent full fiscal year. At the same ticker, Dougan's prior 5 trades show a 4-of-5 pattern of well-timed executions at the 90-day mark, with prior sells consistently followed by declines; however, all post-transaction measurements must await future price action. The complete liquidation of a director's entire stake warrants investor attention as a fundamental departure from partial reductions, particularly given the company's severely depressed valuation and continued unprofitability.

HUMA CEO Niklason sells entire 2.24M-share stake (2,241,045 shares) for $3.7M across 3 days; stock now -76.9% from 52-week high.

Laura E Niklason, HUMA's President, CEO and Director, executed 3 separate sales totaling 2,241,045 shares for $3,733,191.10 at prices ranging from $1.83 to $1.58 on August 18–20, 2025, reducing her holdings from 2.24M shares to 0 shares (a 100.0% reduction). The company faces material headwinds: latest quarterly revenue was only $301,000.00, net income was negative $37,658,000.00, and the full-year result was unprofitable. At the transaction's blended average price of $1.67, the stock is currently -76.9% from its 52-week high of $7.05 and down -29.1% over 30 days. Niklason's cross-ticker sell track record shows a 93.75% well-timed rate over 90 days, and her prior 5 trades at HUMA included 4 well-timed sales at the 90-day mark, suggesting a pattern of selling ahead of declines. The complete liquidation of the CEO's personal stake—coupled with severe revenue contraction, substantial ongoing losses, and sharp recent price deterioration—warrants investor scrutiny.

CCO William Scheessele buys 6,493 HUMA shares at $1.54; stock down -83.7% from 52-week high amid sixth insider buy in 14 days.

Chief Commercial Officer William Scheessele purchased 6,493 shares at $1.54, increasing his holdings from 15,525 to 22,018 shares, during a period of severe equity depreciation: the stock trades -83.7% below its 52-week high of $9.46 and has fallen -49.3% in the past 30 days and -66.4% over 90 days. Critically, this purchase is part of a cluster pattern: 5 other insiders also bought within the past 14 days, indicating multi-executive accumulation at deeply depressed levels. The company is structurally challenged—posting $241,000 in latest-quarter revenue against a $-39,200,000 net loss for the full fiscal year—suggesting the insider buying may reflect views on intrinsic or recovery value rather than operational momentum. The cluster buy during sustained and severe drawdown warrants examination of whether insider knowledge about strategic direction, funding, or partnership development supports these simultaneous purchases at the bottom of the price decline.

CMO Shamik J Parikh buys 7,500 shares of HUMA at $1.55; stock down -84.2% from 52-week high; cluster pattern: 5 other insiders bought in past 14 days

Parikh's purchase of 7,500 shares at $1.55 on 2025-04-10 represents his first HUMA holdings and occurs within a multi-insider buying cluster: 5 other insiders purchased within the past 14 days. The stock trades at $1.49 (current price), -84.2% from its 52-week high of $9.46 and down -51.0% over the past 30 days, indicating a period of acute price compression. The company's recent fundamentals show Revenue $241,000.00 (latest quarter) and Net income $-39,202,000.00, with negative full-year earnings; the Market cap is $231,127,035.84. This synchronized multi-insider buying activity at depressed price levels may warrant investor scrutiny regarding what non-public information or market conditions prompted coordinated accumulation, though no material non-public catalyst is evident in the public record.

CFO Sander Dale A. bought 20,000 shares of HUMA at $1.53; stock down 84.2% from 52-week high; 5 other insiders also bought within 14 days.

CFO Sander Dale A. purchased 20,000 shares at $1.53 on 2025-04-10, doubling his stake from 20,600 to 40,600 shares. This buy occurs after the stock has fallen 84.2% from its 52-week high of $9.46 and is down 51.0% over the past 30 days and 63.8% over 90 days. Notably, 5 other insiders also bought within the past 14 days, forming a cluster buy pattern. The company posted a net loss of $39.2M in the most recent fiscal year against quarterly revenue of $241.0K, indicating material operating losses and cash burn concerns. The insider purchases at depressed price levels combined with simultaneous buying by multiple executives warrant attention as a potential capitulation or contrarian signal, though the company's negative profitability trajectory remains a fundamental headwind.

Director Constantino Michael T. purchased 16,000 shares of HUMA at $1.26 on 2025-04-07, doubling holdings to 32,950 shares amid steep 90-day decline.

Constantino Michael T. purchased 16,000 shares at $1.26, increasing his holdings by 94.4% to 32,950 shares in a financially distressed company: Humacyte reported $241,000 in quarterly revenue, a $-39.2M net loss, and a negative full-year result, with a market cap of $178.4M. The stock has declined 87.8% from its 52-week high and 75.4% over the past 90 days, falling -62.8% in the 30 days preceding this transaction. His prior three purchases at HUMA show mixed outcomes: one achieved -27.1% at 90 days, another -15.1%, and one +0.2%, with only 1 of 3 prior buys well-timed at the 90-day mark. Across his cross-ticker track record, his 3 prior buys averaged -14.0% 90-day returns with a 33.33% win rate, suggesting limited predictive timing ability. A cluster of 2 other insiders also bought within 14 days, though this may reflect regulatory requirement disclosures rather than coordinated conviction. The purchase at a depressed valuation in a loss-making business warrants scrutiny of whether this reflects material non-public information or routine portfolio activity.

Director Sebelius buys 50,000 HUMA shares at $1.32; cluster buy pattern with 2 other insiders in 14 days

Director Kathleen Sebelius purchased 50,000 shares of Humacyte, Inc. at $1.32 on April 8, 2025, increasing her holdings by 121.3% to 91,207 shares total—a substantial accumulation relative to her prior position. This transaction is part of a cluster pattern: 2 other insiders also bought within the same 14-day window, suggesting coordinated or contemporaneous conviction at this price level. The stock has since declined sharply, trading at $1.15 (current price) and down 87.8% from its 52-week high of $9.46, with a 75.4% decline over the past 90 days. Against this backdrop, Humacyte remains unprofitable (latest quarter revenue $241.0K, net income $-39.2M) with a market cap of $178.4M, creating a stark contrast between insider accumulation and deteriorating price action. The cluster buy pattern warrants monitoring to assess whether insiders possess information not yet reflected in public disclosures.

Director Green purchases 6,000 shares of HUMA at $1.29; concurrent insider buy cluster amid -87.8% decline from 52-week high.

Director Charles Bruce Green purchased 6,000 shares at $1.29 on 2025-04-08, increasing his holdings from 2,400 to 8,400 shares (+250.0% vs pre-transaction holdings). The transaction occurs within a 14-day cluster: 2 other insiders also bought during this same window, suggesting coordinated interest at current levels. The stock trades at $1.15, representing -87.8% from its 52-week high of $9.46 and down -75.4% over 90 days. Humacyte reports negative fundamentals—net income of $-39.2M in its most recent full fiscal year and quarterly revenue of only $241.0K—leaving the strategic rationale for this coordinated buying activity unclear against a backdrop of substantial market repricing.

Director Constantino Michael T. buys 4,600 shares of HUMA at $4.39, raising stake 37.2% to 16,950 shares amid -19.2% 90-day decline.

Director Constantino Michael T. purchased 4,600 shares of Humacyte at $4.39 on 2024-12-04, increasing his holdings by 37.2% to 16,950 shares. This follows a steep 90-day decline of -19.2% for the stock and a 52-week setback of -53.2% from the high of $9.46. His cross-ticker track record shows a 50.00% 90-day win rate with an average 90-day return of -7.4% across prior buys, while at HUMA specifically, his 1 prior measurable buy (2023-05-18) yielded +0.2% over 90 days—a narrow win, though his more recent buy on 2024-08-15 at this ticker declined -15.1% over 90 days. The company remains unprofitable with a net loss of $-39.2M in its latest full fiscal year and quarterly revenue of only $241.0K, providing limited fundamental support for the purchase at current valuations.